|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 03/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 25/08/2016 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -1.95% | - | - | 5.73B | |
| -0.66% | +0.44% | +14.25% | +77.26% | 48.36B | |
| +2.20% | +1.41% | +57.98% | +112.68% | 35.8B | |
| +1.26% | -0.57% | -7.95% | +33.74% | 11.83B | |
| -0.46% | -3.06% | +13.55% | +78.32% | 11.48B | |
| -0.37% | -0.37% | +37.53% | +140.99% | 9.01B | |
| +1.52% | +0.39% | +49.34% | -7.78% | 6.99B | |
| -0.17% | -2.92% | +11.72% | +32.23% | 6.7B | |
| -0.59% | -1.95% | +2.18% | +179.57% | 6.42B | |
| -7.92% | -13.61% | -33.87% | -3.07% | 5.3B | |
| Average | -0.52% | -2.10% | +16.08% | +71.55% | 14.76B | |
| Weighted average by Cap. | +0.11% | -0.51% | +24.12% | +82.02% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
